Terminal heart failure
Author:
- 1 October 2014
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Organ Transplantation
- Vol. 19 (5) , 486-493
Abstract
Permanent long-term mechanical circulatory support (MCS) is currently reserved for patients who are transplant ineligible. In light of improved outcomes with current continuous flow devices, increased interest has focused on the potential extension of MCS therapy to ambulatory advanced heart failure patients and as an alternative to cardiac transplantation. Average 1-year and 2-year survival with heart transplantation is about 85 and 80%, and with MCS therapy, it is 85 and 70% (with censoring at transplant). Specific subsets of destination therapy patients enjoy survival out to 2 years, which is comparable with transplant survival. Risk factor analyses identify similar risk profiles for each therapy. Life satisfaction after each is highly dependent on the frequency and severity of adverse events, which are quite different for these interventions. Patients with long expected waiting times will likely be the initial group for triage off the transplant wait list to MCS therapy. MCS has progressively improved and may become a reasonable alternative to transplantation for highly selected patients with long expected waiting time. More routine extension of MCS therapy to the transplant population awaits further reduction of major adverse events, miniaturized devices, and less invasive implant techniques.Keywords
This publication has 32 references indexed in Scilit:
- Sixth INTERMACS annual report: A 10,000-patient databaseThe Journal of Heart and Lung Transplantation, 2014
- Results of the post-market Registry to Evaluate the HeartWare Left Ventricular Assist System (ReVOLVE)The Journal of Heart and Lung Transplantation, 2014
- Clinical variability within the INTERMACS 1 profileCurrent Opinion in Cardiology, 2014
- Results of the Destination Therapy Post-Food and Drug Administration Approval Study With a Continuous Flow Left Ventricular Assist DeviceJACC, 2014
- Prevalence and Prognostic Importance of Changes in Renal Function After Mechanical Circulatory SupportCirculation: Heart Failure, 2014
- Primary graft failure after heart transplantation: Characteristics in a contemporary cohort and performance of the RADIAL risk scoreThe Journal of Heart and Lung Transplantation, 2013
- Quantifying the effect of cardiorenal syndrome on mortality after left ventricular assist device implantThe Journal of Heart and Lung Transplantation, 2013
- The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Official Adult Heart Transplant Report—2013; Focus Theme: AgeThe Journal of Heart and Lung Transplantation, 2013
- Durability of left ventricular assist devices: Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) 2006 to 2011The Journal of Thoracic and Cardiovascular Surgery, 2013
- Fifth INTERMACS annual report: Risk factor analysis from more than 6,000 mechanical circulatory support patientsThe Journal of Heart and Lung Transplantation, 2013